MedPath

To evaluate the efficacy of indrayanadi churna with guda in the management of Bahupitta Kamala

Not yet recruiting
Conditions
Unspecified viral hepatitis without hepatic coma,
Registration Number
CTRI/2020/08/027181
Lead Sponsor
Dr sumant Andhale
Brief Summary

Hypothesis ÷ Indrayanadi churna with guda is effective in the management of Bahupitta kamala

Trial group Drugs ÷ Indrayanadi churna



Contents of Trial Drugs ÷ Indrayana ,Shunthi



Method of preparation÷ Indrayana and Shunthi taken in equal quantity and pounded seperately in fine powder and sieved then mixed together and mixture will be filtered by cotton cloth



Control group Drugs÷ Nishottar churna



Results ÷ Will be assessed maily on the basis of relief in sign and symptoms and level of serum bilirubin, patient will be taken in clinical trial from day  0 to day 28

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients having sign and symptoms of Bahupitta kamala Serum bilirubin above 3 mg/dl.

Exclusion Criteria

Known cases of Ruddhapatha kamala, kumbhakamala, Halimaka ï‚· Serum Bilirubin more than 12mg /dl.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Indrayanadi churna with Guda is effective in the management of Bahupitta kamalaIndrayanadi churna with Guda is effective in the management of Bahupitta kamala in 4 week
Secondary Outcome Measures
NameTimeMethod
Nishottar churna with Triphala kwatha does not have or has less effective in the management of bahupitta kamala in 4 weekNishottar churna with Triphala kwatha has no or less singnificant improvement in sign and symptoms of bahupitta kamala

Trial Locations

Locations (1)

SST Ayurved Mahavidyalaya sangamner

🇮🇳

Ahmadnagar, MAHARASHTRA, India

SST Ayurved Mahavidyalaya sangamner
🇮🇳Ahmadnagar, MAHARASHTRA, India
Dr Sumant Andhale
Principal investigator
8767819788
sumantandhale@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.